國立高雄大學圖資館 |

Language: English

Back

Monoclonal antibodies in headachefro...

Maassen van den Brink, Antoinette.

Monoclonal antibodies in headachefrom bench to patient /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Monoclonal antibodies in headacheedited by Antoinette Maassen van den Brink, Paolo Martelletti.
Reminder of title:	from bench to patient /
other author:	Maassen van den Brink, Antoinette.
Published:	Cham :Springer International Publishing :2021.
Description:	x, 172 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	HeadacheTreatment.
Online resource:	https://doi.org/10.1007/978-3-030-69032-8
ISBN:	9783030690328$q(electronic bk.)

Monoclonal antibodies in headachefrom bench to patient /
Monoclonal antibodies in headachefrom bench to patient /[electronic resource] :edited by Antoinette Maassen van den Brink, Paolo Martelletti. - Cham :Springer International Publishing :2021. - x, 172 p. :ill., digital ;24 cm. - Headache,2197-652X. - Headache..

The CGRP family of neuropeptides and their receptors in the trigeminovascular system -- Pharmacology; where do the mAbs act, gepants vs mAbs -- Monoclonal Antibody Biology -- Guidelines for clinical trials -- Human Models -- CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- Galcanezumab -- Eptinezumab -- Erenumab -- Fremanezumab -- Potential side effects and pregnancy -- Real-world data, clinical practice so far -- Migraine vs Cluster headache and potential other indications.

Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.

ISBN: 9783030690328$q(electronic bk.)

Standard No.: 10.1007/978-3-030-69032-8doiSubjects--Topical Terms:

522789
Headache
--Treatment.

LC Class. No.: RC392 / .M65 2021

Dewey Class. No.: 616.849106

National Library of Medicine Call No.: WL 342

Monoclonal antibodies in headachefrom bench to patient /
LDR:02337nmm a2200349 a 4500 001 598041
003 DE-He213
005 20210428212815.0
006 m d
007 cr nn 008maaau
008 211019s2021 gw s 0 eng d
020 $a 9783030690328$q(electronic bk.)
020 $a 9783030690311$q(paper)
024 7 $a 10.1007/978-3-030-69032-8 $2 doi
035 $a 978-3-030-69032-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RC392 $b .M65 2021
060 4 $a WL 342
072 7 $a MJ $2 bicssc
072 7 $a MED045000 $2 bisacsh
072 7 $a MJ $2 thema
082 0 4 $a 616.849106 $2 23
090 $a RC392 $b .M751 2021
245 0 0 $a Monoclonal antibodies in headache $h [electronic resource] : $b from bench to patient / $c edited by Antoinette Maassen van den Brink, Paolo Martelletti.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a x, 172 p. : $b ill., digital ; $c 24 cm.
490 1 $a Headache, $x 2197-652X
505 0 $a The CGRP family of neuropeptides and their receptors in the trigeminovascular system -- Pharmacology; where do the mAbs act, gepants vs mAbs -- Monoclonal Antibody Biology -- Guidelines for clinical trials -- Human Models -- CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- Galcanezumab -- Eptinezumab -- Erenumab -- Fremanezumab -- Potential side effects and pregnancy -- Real-world data, clinical practice so far -- Migraine vs Cluster headache and potential other indications.
520 $a Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.
650 0 $a Headache $x Treatment. $3 522789
650 0 $a Monoclonal antibodies $x Therapeutic use. $3 194071
650 1 4 $a Internal Medicine. $3 273839
650 2 4 $a Neurology. $3 211583
650 2 4 $a Psychopharmacology. $3 252258
700 1 $a Maassen van den Brink, Antoinette. $3 835390
700 1 $a Martelletti, Paolo. $3 535843
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Headache. $3 710582
856 4 0 $u https://doi.org/10.1007/978-3-030-69032-8
950 $a Medicine (SpringerNature-11650)